October 20, 2025

FDA Okays First Oral GLP-1 for CV Risk

Novo Nordisk’s once-daily GLP-1 tablet reduced major adverse cardiovascular events in high-risk adults, including those without prior heart attack or stroke.

Conexiant

October 20, 2025

Obinutuzumab Wins FDA Nod for Lupus Nephritis

Roche's anti-CD20 antibody improved renal response and allowed for lower corticosteroid use in the phase III REGENCY trial, offering a twice-yearly maintenance option after initial dosing.

Conexiant

October 20, 2025

Tezepelumab FDA Approval Expands Use to Nasal Polyps

AstraZeneca and Amgen’s anti-thymic stromal lymphopoietin biologic reduces nasal polyp burden and corticosteroid use in the phase 3 WAYPOINT trial.

Conexiant

October 17, 2025

FDA Awards Nine CNPV Vouchers to Speed Reviews

Pilot aims to expedite access to high‑impact therapies by streamlining FDA review and strengthening sponsor–agency collaboration.

Conexiant

October 16, 2025

HHS Memo: Fringe Finds a Footing

From wheat fields to Washington: a decades-old fear about skies and 'sprays' rises again, colliding with science, social media, and the machinery of federal policymaking.

KFF Health News

October 15, 2025

Study Describes Patterns in Reported Drug Interactions

Researchers analyze about 177,000 drug interactions to identify key medication safety trends.

Conexiant

October 13, 2025

First Alzheimer's Test for Primary Care

Roche’s FDA-cleared Elecsys pTau181 blood test helps physicians rule out Alzheimer’s pathology early and streamline diagnosis.

Conexiant

October 10, 2025

FDA Broadens Label for Schizophrenia Drug

The FDA has approved a new long-acting injectable treatment option for adults with bipolar I disorder.

Conexiant

October 07, 2025

FDA Announces New Development in Lung Care

The FDA has approved the first treatment in more than a decade for idiopathic pulmonary fibrosis.

Conexiant